These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27422203)

  • 1. MET DNA Alterations in NSCLC-Reply.
    Tong JH; Chan AW; To KF
    Clin Cancer Res; 2016 Jul; 22(14):3699. PubMed ID: 27422203
    [No Abstract]   [Full Text] [Related]  

  • 2. MET DNA Alterations in NSCLC-Letter.
    Mengoli MC; Bertolini F; Tiseo M; Barbieri F; Fiorentino M; Ardizzoni A; Rossi G
    Clin Cancer Res; 2016 Jul; 22(14):3697-8. PubMed ID: 27422202
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
    Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
    Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Yukiue H; Yano M; Fujii Y
    Cancer Sci; 2008 Nov; 99(11):2280-5. PubMed ID: 19037978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
    Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
    Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutation analysis of p16 gene in non-small cell lung carcinomas].
    Fu S; Wang B; Huang C; Liu Q; Zhang G; Li P
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Oct; 16(5):293-5. PubMed ID: 10514534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor molecular profiling of NSCLC patients using next generation sequencing.
    Tsoulos N; Papadopoulou E; Metaxa-Mariatou V; Tsaousis G; Efstathiadou C; Tounta G; Scapeti A; Bourkoula E; Zarogoulidis P; Pentheroudakis G; Kakolyris S; Boukovinas I; Papakotoulas P; Athanasiadis E; Floros T; Koumarianou A; Barbounis V; Dinischiotu A; Nasioulas G
    Oncol Rep; 2017 Dec; 38(6):3419-3429. PubMed ID: 29130105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and Predictive Value of KRAS Mutation in NSCLC.
    Yamamoto S; Washington L; Komiya T
    J Thorac Oncol; 2016 Oct; 11(10):e128-9. PubMed ID: 27663402
    [No Abstract]   [Full Text] [Related]  

  • 12. Sharpening the attack on non-small cell lung cancer.
    Alexander A; Quincy B
    JAAPA; 2016 Nov; 29(11):1-5. PubMed ID: 27787282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.
    Cai YR; Zhang HQ; Qu Y; Mu J; Zhao D; Zhou LJ; Yan H; Ye JW; Liu Y
    Oncol Rep; 2011 Oct; 26(4):877-85. PubMed ID: 21687954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET: a new promising biomarker in non-small-cell lung carcinoma.
    Pérez-Ramírez C; Cañadas-Garre M; Jiménez-Varo E; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacogenomics; 2015; 16(6):631-47. PubMed ID: 25893986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
    Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MET exon 14 mutation, new target in lung sarcomatoid carcinoma].
    Domblides C; Cortot A; Wislez M
    Bull Cancer; 2015 Dec; 102(12):966. PubMed ID: 27064153
    [No Abstract]   [Full Text] [Related]  

  • 20. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.